Vistagen Therapeutics, Inc.
As of Oct 22, 2026, Vistagen Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $0.19, 96.1% below its 52-week high and below its 200-day average, which is falling.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is VTGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VTGN among Biotechnology525th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …525 | VTGN | Stage 4 · wk 1 | 5 | −48.6% |
Vistagen Therapeutics: quick answers
What stage is Vistagen Therapeutics in?
As of Oct 22, 2026, Vistagen Therapeutics (VTGN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean
Is Vistagen Therapeutics in an uptrend?
No. Vistagen Therapeutics is in a Stage 4 downtrend. It trades 58.8% below its 200-day average, which is falling.
How far is Vistagen Therapeutics from its 52-week high?
Vistagen Therapeutics closed at $0.19 on Oct 22, 2026, 96.1% below its 52-week high of $4.90. Its 52-week low is $0.19.
How has Vistagen Therapeutics performed over the past year?
As of Oct 22, 2026, Vistagen Therapeutics is down 95.5% over the past year and down 72.1% so far in 2026.
Which sector and industry is Vistagen Therapeutics in?
Vistagen Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.